Abstract:Objective: Methylation of the promoters of SHOX2 and RASSF1A are potentially informative biomarkers for the diagnosis of early lung adenocarcinoma (LUAD). Abnormal methylation of SHOX2 and RASSF1A promoters may promote the occurrence and facilitate the progression of LUAD. Materials and Methods: We selected 54 patients with early LUAD and 31 patients with benign lung nodules as a NJDT cohort and evaluated their DNA methylation and mRNA sequencing levels. The DNA methylation sequencing, mRNA sequencing, and clinical data for patients with LUAD were obtained from The Cancer Genome Atlas, and served as a TCGA cohort. We evaluated the diagnostic potential of a SHOX2 and RASSF1A combined promoter methylation assay for detection of early LUAD in the NJDT cohort. Then we explored the promoter methylation levels of SHOX2 and RASSF1A and their gene expression between normal and tumor samples at different stages in both cohorts. Pathways enriched between tumor and normal samples of methylation-positive patients in the NJDT cohort were analyzed. Results: In the NJDT cohort, the sensitivity of the combined promoter methylation assay on tumor samples was 74.07%, the sensitivity on paired tumor and paracancerous samples was 77.78%, and the specificities in both contexts were 100%. The combined promoter methylation-positive patients had clinicopathologic features including older age, larger tumors, deeper invasion, and higher Ki-67 expression. In both cohorts, SHOX2 expression increased and RASSF1A expression decreased in tumor samples. The promoter methylation level of SHOX2 and RASSF1A was significantly higher in tumor samples at stage I-II than that in normal samples. The promoter methylation levels of these two genes were both negative associated with their expression in early tumor samples. In the NJDT cohort, methylation-positive patients of both individual SHOX2 and RASSF1A assays exhibited upregulation of folate acid metabolism and nucleotide metabolism in tumor samples. The SHOX2 methylation-positive and RASSF1A methylation-positive patients showed the downregulation of pathways related to cell proliferation and apoptosis and pathways involved in DNA repair, cell growth and cell adhesion, respectively. Conclusion: The combined promoter methylation assay for SHOX2 and RASSF1A can be used for screening and diagnosis of early LUAD, with good sensitivity and specificity. The promoter methylation levels of SHOX2 and RASSF1A were associated with their abnormal mRNA expression, and affected DNA instability, cell proliferation, apoptosis and tumor microenvironment in patients with LUAD.

Association of the SHOX2 and RASSF1A methylation levels with the pathological evolution of early-stage lung adenocarcinoma

Performance Evaluation of SHOX2 and RASSF1A Methylation for the Aid in Diagnosis of Lung Cancer Based on the Analysis of FFPE Specimen

The Diagnostic Potential of SHOX2 and RASSF1A DNA Methylation in Early Lung Adenocarcinoma

The combination of SHOX2 and RASSF1A DNA methylation had a diagnostic value in pulmonary nodules and early lung cancer

Diagnostic performance of RASSF1A and SHOX2 methylation combined with EGFR mutations for differentiation between small pulmonary nodules

Short Stature Homeobox 2 Methylation As A Potential Noninvasive Biomarker in Bronchial Aspirates for Lung Cancer Diagnosis

Predictive Value of Unmethylated RASSF1A on Disease Progression in Non-Small Cell Lung Cancer Patients Receiving Pemetrexed-Based Chemotherapy

A comprehensive diagnostic scheme of morphological combined molecular methylation under bronchoscopy

Development of a Noninvasive Method for Early Stage Lung Cancer Diagnosis Based on Methylation Analysis of SHOX2 and PTGER4

DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis.

DNA methylation analysis in plasma for early diagnosis in lung adenocarcinoma

Detection of SHOX2 DNA Methylation by Methylation-Specific PCR in Non-Small Cell Lung Cancer.

Expressions of SHOX2, RASSF1A and PTGER4, and the relationship between their methylation and clinicopathological characteristics in patients with lung cancer

Utility of SHOX2 and RASSF1A gene methylation detection on the residual cytology material from endobronchial ultrasound-guided transbronchial needle aspiration

Association of DNA methylation of RASSF1A and SHOX2 with lung cancer risk: A systematic review and meta-analysis

Diagnostic Value of Shox2 Dna Methylation in Lung Cancer: a Meta-Analysis

Combined Methylation of SHOX2 and RASSF1A Genes in Diagnosing Malignant Pleural Effusion

Identification of Diagnostic DNA Methylation Biomarkers Specific for Early-Stage Lung Adenocarcinoma.

Diagnostic Significance of SHOX2 Gene Methylation in Non-small Cell Lung Cancer

Novel Blood-Based Hypomethylation of SH3BP5 is Associated with Very Early-Stage Lung Adenocarcinoma.

DNA Methylation Profiling Identifies the HOXA 11 Gene As an Early Diagnostic and Prognostic Molecular Marker in Human Lung Adenocarcinoma